Literature DB >> 29452959

Differential expressions of MDM2 and TAP73 in cancer and cancer-adjacent tissues in patients with non-small-cell lung carcinoma.

B Wang1, X Liu1, H Liu2, J Guo1, T Zhang1, N Zhou1, Y Ma1, H Yu1, L Chen1, Z Ren1, K Fan1, X Tian3.   

Abstract

AIM: To investigate the differences in mRNA and protein expressions of MDM2 (mouse double minute 2 homolog) and P73 in cancer and cancer-adjacent tissues in patients with non-small-cell lung carcinoma (NSCLC).
MATERIALS AND METHODS: We compared the protein expressions of MDM2 and P73 in lung cancer and cancer-adjacent tissues in NSCLC patients by IHC (immunohistochemistry) and WB (Western blot). We divided the NSCLC patients into two subgroups, adenocarcinoma and squamous carcinoma. The mRNA expressions of two main isoforms of P73, TAP73 and DNP73, as well as the ratio of DNP73/TAP73 were analyzed by qPCR (quantitative real-time PCR) in the two tissues in all NSCLC patients and in patients with adenocarcinoma or squamous carcinoma, respectively.
RESULTS: WB results did not show significant differences in MDM2 and P73 protein expressions in lung cancer and cancer-adjacent tissues. However, IHC results indicated that MDM2 expression significantly increased in cancer tissues in female patients, but not male patients. In addition, TAP73 mRNA expression significantly increased in cancer tissues in all NSCLC patients (p=0.002) and in patients with adenocarcinoma (p=0.01); while there was no significant difference in DNP73 mRNA expression. Hence the fold-change of DNP73/TAP73 ratio significantly decreased (p=0.0003) in cancer tissues in all NSCLC patients and in patients with adenocarcinoma.
CONCLUSIONS: TAP73 mRNA expression significantly increased in cancer tissues than cancer-adjacent tissues in all NSCLC patients and in patients with adenocarcinoma. Meanwhile, the fold-change of DNP73/TAP73 ratio was similar to TAP73. MDM2 protein expression significantly increased in cancer tissues in female NSCLC patients.
Copyright © 2017 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Lung cancer; MDM2 (mouse double minute 2 homolog); Squamous carcinoma; TAP73

Year:  2018        PMID: 29452959     DOI: 10.1016/j.rppnen.2017.08.008

Source DB:  PubMed          Journal:  Pulmonology        ISSN: 2531-0429


  5 in total

Review 1.  Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity.

Authors:  Sue Haupt; Ygal Haupt
Journal:  Front Genet       Date:  2021-02-16       Impact factor: 4.599

Review 2.  The p53 family member p73 in the regulation of cell stress response.

Authors:  Svetlana Zvereva; Aleksandra Dalina; Igor Blatov; Julian M Rozenberg; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Carlo Ganini; Nikolai A Barlev
Journal:  Biol Direct       Date:  2021-11-08       Impact factor: 4.540

3.  The expression of mouse double minute 2 homolog and P73 had no correlation with growth arrest DNA damage-inducible gene 45α in patients with non-small-cell lung carcinoma: A STROBE-compliant study.

Authors:  Bo Wang; Chaoyang Liang; Huifeng Liu; Jixing Lin; Bailin Wang; Kaijie Fan; Zhipeng Ren; Bin Wang; Tong Li; Kang Qi; Xiaodong Tian
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

4.  Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.

Authors:  Jianhao Xu; Liwei Ni; Fenglun Zhao; Xiaoxiao Dai; Jialong Tao; Jia Pan; Aiming Shi; Zhu Shen; Cunjin Su; Yusong Zhang
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

Review 5.  Dual Role of p73 in Cancer Microenvironment and DNA Damage Response.

Authors:  Julian M Rozenberg; Svetlana Zvereva; Alexandra Dalina; Igor Blatov; Ilya Zubarev; Daniil Luppov; Alexander Bessmertnyi; Alexander Romanishin; Lamak Alsoulaiman; Vadim Kumeiko; Alexander Kagansky; Gerry Melino; Nikolai A Barlev
Journal:  Cells       Date:  2021-12-13       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.